INTRODUCTION
One of the most interesting questions confronting the LPS signal transduction field during the 1990s concerned the identity of a postulated co-receptor for LPS. In 1990, LPS was shown to bind to CD14 on the surface of mononuclear phagocytic cells, 1 and subsequent gene knockout work proved that the interaction was an important one in LPS signal transduction. 2 However, since CD14 was known to be a glycosylphosphoinositol-tethered protein, bereft of a cytoplasmic domain, it had no obvious means of evoking a transmembrane signal. How, then, could the LPS signal be transduced into the cytoplasm?
At one time or another, workers in the LPS field held that LPS might signal 'non-specifically'; that is, without the aid of a protein intermediary within the membrane. Rather, LPS itself might insert into the membrane, and perturb membrane structure in such a way as to initiate a signal. Another school of thought held that a proteolytic enzyme within the membrane or within the cytoplasm might be activated in response to LPS. Among other protein targets of LPS, virtually every type of signaling molecule known has been mentioned, alongside structural proteins (e.g., those involved in vesicle trafficking, 3 or microtubular assemblies 4 ). Conventional tools of gene identification, including expression cDNA cloning, subtraction cDNA cloning, the use of the yeast two-hybrid system, and physical approaches to the detection of interactions between proteins all failed to disclose a co-receptor that would bind LPS alongside CD14 and initiate signal transduction.
The co-receptor, now known to be the Toll-like receptor 4 (Tlr4) was finally identified as a result of positional cloning work involving the C3H/HeJ and C57BL/10ScCr mouse strains, of which a longer account has been written separately. 5 Each of these strains has been known for many years to be profoundly resistant to LPS. 6, 7 The reason for their resistance has emerged with the discovery that both strains bear mutations affecting the Tlr4 locus. This finding was the outcome of 5 years of intensive genetic and physical mapping work, which culminated in the determination that: (i) Tlr4 is the sole gene in the Lps critical region; 8 (ii) a point mutation modifies the Tlr4 cytoplasmic domain in C3H/HeJ mice; 9 and (iii) a deletion removes the entire Tlr4 coding region in C57BL/10ScCr mice. 9, 10 The essential role of Tlr4 in LPS signaling was later confirmed by analysis of mice with a Tlr4 knockout mutation. 11
OTHER MOLECULES PROPOSED AS LPS SIGNAL

TRANSDUCERS
As mentioned, other candidate transducers have been proposed, some before and some after the identification of Tlr4 as the product of Lps. Among these, CD18 was suggested to bind LPS, and transduce its signal. 12, 13 Heterotrimeric G-proteins were also mentioned as transducers, 14 and the platelet activating factor (PAF) receptor was also discussed in this connection. 15, 16 Two candidates deserve particular mention, however, because their involvement in LPS signaling has been discussed persistently, and we will explain why we are certain that they are not, in fact, the relevant signaling molecules. The first molecule is a small GTP binding protein known as Ran or TC4. The second is a relative of Tlr4, known as Tlr2.
Ran/TC4 first came to the attention of workers in the LPS signaling field when it was identified in an expression cDNA cloning effort, designed to detect restored LPS competence in lymphoid cells derived from C3H/HeJ mice. 17 While Ran/TC4 cDNA transfection reportedly yields what might best be described as weak complementation of the defect in C3H/HeJ mice, it does not fully restore LPS sensitivity, as is the case when the normal isoform of Tlr4 is expressed by these cells. 18, 19 Moreover, although it has been claimed that a mutation affecting Ran/TC4 resides within the 3′-UTR of the C3H/HeJ Ran/TC4 gene, we have been unable to confirm the existence of such a mutation ( Fig. 1 ). Finally, while the Ran/TC4 gene reportedly resides on mouse chromosome 4, there are no genetic mapping data to support such a localization. To the contrary, complete genomic sequence data show that it does not. For all of these reasons, we feel that Ran/TC4 cannot be regarded as a participant in the LPS signal transduction pathway.
The solitary nature of the LPS signal transduction pathway was indicated from the very start by the fact that mutations at a single locus (Lps) are able to completely abolish LPS signal transduction, as witnessed in C3H/HeJ and C57BL/10ScCr mice. It is now know that in the latter strain, the Tlr4 locus is deleted entirely, while in the former strain, a point mutation modifies the cytoplasmic domain of the Tlr4 receptor so as to yield co-dominant inhibition of LPS signaling in heterozygotes. Insofar as the modification of a single amino acid is sufficient to wreak such a profound effect on LPS signaling, it may be said that accessory pathways are of negligible importance. This observation spoke strongly against any possibility that Tlr2 might have a supportive role in LPS signaling. The possibility that Tlr2 might be required for LPS signaling was effectively ruled out by knockout work performed by Takeuchi et al. 20 who showed that Tlr2-deficient mice respond normally to LPS stimulation. On the other hand, Tlr2-deficient mice fail to mount an adequate response to certain Gram-positive organisms, 21 and are unable to respond to peptidoglycan 20 and bacterial lipopeptides. 22 It cannot be excluded that other proteins, yet to be identified, might participate in the LPS signal transduction complex. It is possible that some exotic LPS species use different signaling pathways than enteric LPS molecules. And it is possible that accessory pathways may exist in cells treated with activators such as interferon-γ. But for enteric LPS molecules and naïve macrophages, the case for a single LPS signal transducer appears to be sealed, and the transducer is Tlr4.
WHAT DOES THE IDENTITY OF THE LPS TRANSDUCER TELL US ABOUT INNATE IMMUNITY IN GENERAL?
Tlr4 is one member of a family that now includes 10 mammalian representatives. The prototypic gene, Toll, was shown in 1996 to initiate signals required for effective defense against fungal infection in Drosophila. 23 As already mentioned, Tlr2 acts as a sensor of Gram-positive infection. Tlr9 is now known, again as the result of knockout studies performed by Akira and colleagues, to detect unmethylated bacterial DNA. 24 The picture that emerges is one in which each Toll-like receptor 'sees' a discrete part of the chemical makeup of microbial pathogens. Collectively, then, the Toll-like receptors are able to provide early warning of infection, and offer the host protection against microbial disease.
In Drosophila, Toll does not act as a classical 'pattern recognition receptor', in that it has no direct contact with any part of the fungal pathogen that it detects. Rather, fungal infection leads to the proteolytic cleavage of a hormone, liberating the ligand Spätzle, which engages and activates Toll. By contrast, Tlr4 directly engages bacterial LPS. This has been demonstrated by genetic complementation work, carried out independently by Poltorak et al. 18 and Lien et al. 25 Using different cellular systems, both groups of workers showed that the species specificity of certain LPS partial structures is fully attributable to the species origin of Tlr4. As such, Tlr4 appears to 'read' the structure of an LPS molecule. Furthermore, structural variation in Tlr4 itself can affect the response to a given LPS ligand.
For this reason, genetic variation in Tlr4 structure may determine host susceptibility to specific infectious organisms. Corresponding, variation at other Toll-like receptor loci may have a similar effect. In aggregate, the genetic makeup of an individual and all Tlr loci may have much to say with respect to the likelihood that that individual will suffer an overwhelming bacterial infection in the course of a normal lifetime.
WHAT IS THE NATURE OF GENETIC
VARIATION AT TLR4?
A total of 36 strains of endotoxin-resistant mice and several hundred normal humans from different ethnic backgrounds have now been examined by directly sequencing the entire coding region of Tlr4. 26, 27 In addition, several 'outgroups' have been sequenced, including the baboon, orangutan, chimpanzee, and gorilla. The recent evolution of Tlr4 has been such that more variation has appeared among rodents than among humans. 26 In humans, and indeed among all primates, changes in Tlr4 structure have been comparatively retarded. An excess of rare coding polymorphisms is observed in the Tlr4 gene, consistent with the likelihood that the locus has been subject to strong purifying selection and has not undergone diversification in the manner known to have occurred with, for example, components of the major histocompatibility complex. This may reflect the fact that many mutations of Tlr4 are deleterious by virtue of their tendency to confer hypersensitivity to LPS, or non-specific activation of the receptor outright. 27 On the other hand, mutations that diminish sensitivity to LPS are known to predispose to Gram-negative infection 28, 29 and, as such, hypomorph mutations would also tend to be removed from the population.
The more distant evolution of Tlr4 genes can be traced in mammals by the method of parsimony analysis. While there are 10 Tlr loci in mammals today, as well as at least three Tlr pseudogenes, it is probable that a relatively short time ago there were only 9 active genes, given that Tlrs 1 and 6 diverged in the recent evolutionary past. Tlrs 3 and 5 split from each other a short time before that, as did Tlrs 7 and 8. Since the Tlr2 has been identified in birds, it is likely that the split between Tlr2 and the progenitor of Tlrs 1 and 6 occurred at least 310 million years ago. It is less clear that Tlr4 is represented in birds, and given the high level of resistance to endotoxin observed in all classes of the phylum Chordata save mammals, we might imagine that it has acquired a different function if it does exist.
The cytoplasmic domain of Toll-like receptors, with its prominent TIR (Toll/IL-1 receptor) motif, evolves much more slowly than the ectodomain of each Tlr. This observation bespeaks a need for changes in the structure of the ectodomain pursuant to changes in the microbial environment with which the host must contend.
THE FUTURE OF TLR RESEARCH
A number of pressing questions guide investigation of Tlr genetics, structure, and function at the present time. Exactly how does Tlr4 engage endotoxin? Are Tlr4 and CD14 sufficient for LPS signal transduction? Is MD2 also required, as has been suggested by transfection studies? 30 Are there other proteins yet to be discovered, as genetic evidence hints? 31 Our understanding of Tlr4 signal transduction is still fairly rudimentary. It is believed that all members of the Toll-like receptor family, as well as IL-1 and IL-18 receptors, signal through activation of the TIR containing cytoplasmic protein MyD88. It is also believed that recruitment of IL-1 receptor associated kinase (IRAK) and TRAF6 are important events, in turn leading to the activation of TAK1, phosphorylation of IκB, and nuclear translocation of NF-κB. However, many other protein kinase cascades are activated by LPS, and there are certainly differences in cellular responses that follow activation of different Toll-like receptors. It must, therefore, be anticipated that other connections between members of the Toll-like receptor family and proteins involved in signal transduction will be established in the near future. Already, considerable progress has been made with the elucidation of the structure of the cytoplasmic domain of two members of the family (Tlr1 and Tlr2) by Xu and co-workers. 32 But the structure of the ectodomain of all Tlrs remains a matter of pure guesswork at present. Do mutations affecting Tlr4 or other members of the family cause notable immunocompromise in humans? Schwartz and co-workers have suggested that the most common Caucasian polymorphism of Tlr4 -a double amino acid substitution affecting the ectodomain of the proteinrepresents a hypomorph, 33 and as such we might anticipate that individuals bearing this mutation in heterozygous form (and certainly in homozygous form) would prove to be less responsive to Gram-negative infections at a early stage. However, there are no direct data to support a role in sepsis as yet. If the pattern of mutation of all Tlrs conforms to that which we have established for Tlr4, 26 a sizable fraction of the population might be expected to have no normal allele of one or more of the Tlrs. Such individuals might also prove to be immunocompromised.
It might also be expected that activating mutations of Tlrs could lead to the development of autoimmune phenotypes, in which constitutive signaling, occurring systemically, or within specific clones of cells, could cause unwanted inflammation. A few nanograms of Tlr4, for example, if maximally activated, are sufficient to have a lethal effect in a mouse. A far smaller amount of maximally activated Tlr4, or the normal complement of submaximally activated Tlr4, might have sub-lethal, but very noticeable effects.
Identification of Tlr4 as the sole conduit for LPS signal transduction 279
The search for the LPS receptor was ultimately successful in its own right, but has proved to be all the more exciting in the sense that it showed LPS to be the model inducer of innate immune response that all workers in the field had considered it to be. The discovery that Tolllike receptor 4 transduces the LPS signal immediately illuminated, in large part, the mechanism by which all microbial molecules are sensed by the innate immune system. The minute quantities of Toll-like receptors that are required to achieve this end have proven something of a hindrance to investigation of Tlr function, just as they prove to be a hindrance to the initial discovery of how LPS signal occurs. Yet there is reason for confidence that many of the questions just presented will yield to careful and vigorous inquiry.
